-
Mashup Score: 8
Neoadjuvant short-course radiotherapy (SCRT) followed by CAPOX and camrelizumab (a programmed cell death protein 1 monoclonal antibody) has shown potential clinical activity for locally advanced rectal cancer (LARC) in a phase II trial. This study aimed to further confirm the efficacy and safety of SCRT followed by CAPOX and camrelizumab compared to long-course chemoradiotherapy (LCRT) followed by CAPOX alone as neoadjuvant treatment for LARC.
Source: www.annalsofoncology.orgCategories: General Medicine NewsTweet
-
Mashup Score: 4Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial - 5 month(s) ago
Nature Medicine – As presented at the 2025 ASCO GI Cancers Symposium: in the phase 3 BREAKWATER trial, patients with previously untreated BRAF V600E metastatic colorectal cancer received the BRAF…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
Publication here in @NatureMedicine https://t.co/u4GiG7IHtI
-
-
Mashup Score: 4Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial - 5 month(s) ago
Nature Medicine – As presented at the 2025 ASCO GI Cancers Symposium: in the phase 3 BREAKWATER trial, patients with previously untreated BRAF V600E metastatic colorectal cancer received the BRAF…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
Publication here in @NatureMedicine https://t.co/u4GiG7IHtI
-
-
Mashup Score: 8
Nivolumab plus ipilimumab showed superior progression-free survival versus nivolumab across all treatment lines, with a manageable safety profile, in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer. These results, together with the first-line results of superior progression-free survival with nivolumab plus ipilimumab versus chemotherapy, suggest nivolumab plus ipilimumab as a potential new standard of care for patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
Now published in @TheLancet https://t.co/prm3FBA16U
-
-
Mashup Score: 4Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial - 5 month(s) ago
Nature Medicine – As presented at the 2025 ASCO GI Cancers Symposium: in the phase 3 BREAKWATER trial, patients with previously untreated BRAF V600E metastatic colorectal cancer received the BRAF…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
Publication here in @NatureMedicine https://t.co/u4GiG7IHtI
-
-
Mashup Score: 4Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial - 5 month(s) ago
Nature Medicine – As presented at the 2025 ASCO GI Cancers Symposium: in the phase 3 BREAKWATER trial, patients with previously untreated BRAF V600E metastatic colorectal cancer received the BRAF…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
Publication here in @NatureMedicine https://t.co/u4GiG7IHtI
-
-
Mashup Score: 3Program Guide – ASCO Meeting Program Guide - 5 month(s) ago
The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC Atul Sharma Department of Medical Oncology, All India Institute of Medical Sciences Atul Sharma , Sushmita Pathy , Sunil Kumar , Sujoy Pal , Akash Kumar , Nihar Dash , Raja Pramanik , Sandeep Bhoriwal , Amol Patel , Ranjit Sahoo , Babita Kataria , Sanjay Thulkar , Vishnu Sreenivas , Aparna Sharma , Hari Krishna Raju Sagiraju , Vinod Sharma Department of Medical Oncology, All India Institute of Medical Sciences, Department of
Source: meetings.asco.orgCategories: General Medicine News, Hem/OncsTweet-
https://t.co/xxAwWjPUfY
-
-
Mashup Score: 2Program Guide – ASCO Meeting Program Guide - 5 month(s) ago
Marwan Fakih Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center Marwan Fakih , Neil Segal , Benjamin Schlechter , Thierry Andre , Filippo Pietrantonio , Benny Johnson , Alexander Vasilyev , Smitha Krishnamurthi , Salvatore Siena , Wells Messersmith , Virgilio Souza E Silva , Andrew Paulson , Elena Elez , Cathy Eng , Sabine Tejpar , Michel Ducreux , Wei Wu , Joseph Grossman , Eric Van Cutsem , Manuel Hidalgo Department of Medical Oncology and Therapeutics
Source: meetings.asco.orgCategories: General Medicine News, Hem/OncsTweet-
https://t.co/4j0T68darh
-
-
Mashup Score: 2Program Guide – ASCO Meeting Program Guide - 5 month(s) ago
The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC Vincent Picozzi , Khurum Khan , Pascal Hammel , Michele Reni , Daniel Lin , Woo Jin Lee , Roberto Pazo Cid , Vaibhav Sahai , Andres Munoz Martin , Jianjun Liu , Ende Zhao , Ewa Carrier , Teresa Macarulla Virginia Mason Hospital and Medical Center, University College London Hospitals NHS Foundation Trust, Paris-Saclay University, Digestive and Medical Oncology Department, Paul Brousse Hospital, APHP, Department of Medical
Source: meetings.asco.orgCategories: General Medicine News, Hem/OncsTweet-
https://t.co/qHBCGSJwuc
-
-
Mashup Score: 2Program Guide – ASCO Meeting Program Guide - 5 month(s) ago
The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC Hannah Williams , Emmanouil Fokas , Markus Diefenhardt , Sabrina Lin , Li-Xuan Qin , Claus Rodel , Julio Garcia-Aguilar Memorial Sloan Kettering Cancer Center, University Hospital Cologne, University of Frankfurt, University Hospital Frankfurt This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Source: meetings.asco.orgCategories: General Medicine News, Hem/OncsTweet-
https://t.co/MBnh5c0Lv6
-
🔥SPRING-01🔥 While ICI efficacy has been debatable in pMMR CRC, here are a few additional trials showing that addition of ICI to RT--> chemo can augment response STELLAR-II (Sintilimab) (attached image) UNION (Camrelizumab): https://t.co/gKZvO8zlGO TORCH (Toripalimab): https://t.co/yuvbBkEWDi https://t.co/ShQJ8oFFkM